|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
June 2004 Spray-on Contraceptive Trial Begins
Testing that could result in the first-ever contraceptive delivered by a spray is slated to begin this year in Australia. The trial will assess one or more formulations of Nestorone® in a spray to determine a formulation that could suppress ovulation. The product brings together the Metered-Dose Transdermal System (MDTS®) developed by FemPharm Pty Ltd., a wholly owned subsidiary of Acrux Limited, and Nestorone, a versatile synthetic progestin extensively studied by the Population Council. MDTS is a small and easy-to-use drug applicator that will deliver a pre-set, fast-drying dose of Nestorone to the skin, creating an invisible, subdermal reservoir from which the drug will slowly be absorbed into the bloodstream. Sandra P. Arnold, vice president of Corporate Affairs for the Population Council, noted that the goal of the partnership with Acrux is to “provide women with a contraceptive delivery system that is affordable, safe, reversible, and easy to use.” The clinical trial will be conducted at the Sydney Centre for Reproductive Health Research, under the direction of principal investigator Ian Fraser, and will take less than two years. Fraser is a member of the Population Council’s International Committee for Contraception Research and a professor of reproductive medicine at the University of Sydney. Acrux Limited is a group of companies engaged in the development of proprietary transdermal and cosmeceutic products, using technology licensed from Monash University, Melbourne, Australia. See Also
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
